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Background: Central nervous system primitive neuroectodermal tumours (CNS PNETs) are embryonal tumours occurring
predominantly in children. Current lack of knowledge regarding their underlying biology hinders development of more effective
treatments. We previously identified WNT/b-catenin pathway activation in one-third of CNS PNETs, which was potentially linked
to a better prognosis. In this study, we have extended our cohort, achieving a statistically significant correlation with prognosis.
We additionally investigated the biological effects of WNT/b-catenin pathway activation in tumour pathogenesis.
Methods: A total of 42 primary and 8 recurrent CNS PNETs were analysed for WNT/b-catenin pathway status using b-catenin
immunohistochemistry. Genomic copy number and mRNA expression data were analysed to identify a molecular profile linked to
WNT/b-catenin pathway activation.
Results: Pathway activation was seen in 26% of CNS PNETs and was significantly associated with longer overall survival.
Genes displaying a significant difference in expression levels, between tumours with and without WNT/b-catenin pathway
activation, included several involved in normal CNS development suggesting aberrant pathway activation may be disrupting this
process.
Conclusion: We have identified WNT/b-catenin pathway status as a marker, which could potentially be used to stratify
disease risk for patients with CNS PNET. Gene expression data suggest pathway activation is disrupting normal differentiation in
the CNS.
Central nervous system tumours are the most common solid
tumours during childhood. Central nervous system primitive
neuroectodermal tumours (CNS PNETs) are high-grade embryonal
tumours that occur at any extracerebellar site in the CNS and are
composed of undifferentiated or poorly differentiated neuro-
epithelial cells (Louis et al, 2007). Currently, outcome for children
with CNS PNET is poor with a 5-year survival rate of 31–53%
(Reddy et al, 2000; Geyer et al, 2005). Pineoblastomas are highly
malignant PNETs of the pineal gland, which histologically
resemble other PNETs of the CNS (Louis et al, 2007). In the
United Kingdom, pineoblastomas are treated with protocols
similar to CNS PNETs (Pizer et al, 2006).
Relatively little research has been undertaken to elucidate the
molecular basis of CNS PNETs. Previously they have been grouped
with the histologically similar tumour medulloblastoma; both being
composed of poorly differentiated round ‘small blue’ cells with
scant cytoplasm (Louis et al, 2007). Currently, CNS PNETS are
treated with therapy designed for high-risk medulloblastoma
(Li et al, 2005). However, several studies suggest this approach is less
effective in CNS PNET than medulloblastoma (Paulino and
Melian, 1999; Reddy et al, 2000; Hong et al, 2004). Recent research
has suggested there are molecular and genetic differences between
CNS PNET and medulloblastoma (Pomeroy et al, 2002; Inda et al,
2005; McCabe et al, 2006; Pfister et al, 2007a).
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An increased understanding of the molecular genetic basis of
CNS PNET is therefore needed and will allow a more targeted
approach to therapy. Recent research has started to elucidate the
biological and genetic characteristics of CNS PNET and identify
molecular subgroups (Miller et al, 2011; Picard et al, 2012). We
previously published a study showing approximately one-third of
supratentorially located CNS PNETs displayed WNT/b-catenin
pathway activation, which was potentially associated with a better
prognosis (Rogers et al, 2009). The WNT/b-catenin pathway has
been found to be aberrantly activated in a number of cancers
including medulloblastoma (Ellison et al, 2005; Thompson et al,
2006; Kool et al, 2008; Northcott et al, 2010). The pathway has a role
in many cellular functions including proliferation, differentiation and
migration. When the pathway is inactive, the downstream effector
b-catenin is bound to a cytoplasmic complex, which phosphorylates
it targeting the protein for degradation. When a WNT ligand binds
to its receptor the pathway is activated leading to the destabilisation
of the cytoplasmic complex, preventing phosphorylation of b-catenin
and allowing translocation to the nucleus where it acts as a tran-
scriptional co-activator (Morin, 1999).
In this study, we aimed to confirm the link between WNT/
b-catenin pathway activation and prognosis in supratentorially
located CNS PNET and additionally investigate the biological
effects of pathway activation. We have extended our cohort of
supratentorially located CNS PNETs analysed for WNT/b-catenin
pathway status using b-catenin immunohistochemistry (IHC),
through which we demonstrated a significant link with a better
survival. In addition, we utilised previously published genomic
copy number and mRNA expression array data to identify a
molecular profile linked to CNS PNETs with WNT/b-catenin
pathway activation (Li et al, 2009; Miller et al, 2011). Genes
involved in development of the CNS were identified suggesting this
process may be disrupted in the tumours through aberrant
pathway activation. Central nervous system primitive neuroecto-
dermal tumours with pathway activation displayed lower levels of
markers of neuronal differentiation compared with other tumours
supporting this hypothesis.
MATERIALS AND METHODS
Sample information. Tumour samples were obtained from the
Children’s Cancer and Leukaemia Group (CCLG) and the
Cooperative Human Tissue Network (CHTN). Twelve snap-frozen
supratentorially located CNS PNETs and one pineoblastoma were
obtained. Three CNS PNETs were recurrences, one with the paired
primary included in the study. Ten of the CNS PNETs and the one
pineoblastoma were run on Affymetrix U133 plus 2 arrays
(Affymetrix, Santa Clara, CA, USA). Ten CNS PNETs were used
for qPCR analysis, eight of which were also run on the arrays.
Fifty retrospective supratentorial CNS PNETs and nine pine-
oblastomas were obtained as paraffin-embedded blocks following
formalin fixation. Seven CNS PNETs were recurrences. For six the
paired primary was also included in the study. For one patient, a
tumour sample was obtained from a second surgery (1 week later).
Twenty-three of the primary and seven recurrent CNS PNETs plus
five primary pineoblastomas were originally analysed in a previous
study (Rogers et al, 2009). In this study, an additional 19 primary
and 2 recurrent CNS PNETs, plus 4 primary pineoblastomas were
added to the cohort. Samples were analysed using whole sections
or on a tissue microarray (TMA). For TMAs, following diagnostic
pathology review representative areas of tumour tissue were selected.
Three cores from each tumour were included.
Clinical information was obtained from CCLG, CHTN and local
centres. Multiple Centre Research Ethics Committee (MREC, 04/
MRE04/72) approval was obtained. Consent for use of tumour
samples was taken in accordance with national tumour banking
procedures and the Human Tissue Act. Work was conducted in
premises licensed under the Human Tissue Act.
Immunohistochemistry. Immunohistochemistry was carried out
on TMAs and whole sections as described previously (Ridley et al,
2008). Slides were incubated with b-catenin (1 in 500, Cell
Signaling Technology, Danvers, MA, USA), map2 (1 in 200,
Abcam, Cambridge, UK) and synaptophysin (1 in 200, Dako, Ely,
UK). b-Catenin data from our previous study were used in our
analysis (Rogers et al, 2009). Immunohistochemistry was carried
out for an additional 23 samples, 19 CNS PNET and 4
pineoblastoma, as previously described (Rogers et al, 2009). Briefly,
b-catenin was scored as nuclear or non-nuclear. The nuclear
stained samples were divided into two groups defined by the
percentage of positive nuclei. Samples with o10% of nuclei
positive were labelled as ‘low’ and 410% as ‘high’. Map2 was
scored as positive or negative. Positive samples were split into two
groups showing high and low intensity staining. Synaptophysin
was scored as positive or negative.
Overall, and progression-free, survival were investigated using
the Kaplan–Meier method. The differences were estimated using
the log-rank (Mantel–Cox) test. Overall survival (OS) was defined
as the time between date of original diagnosis and date of death.
Progression-free survival (PFS) was defined as the time between
date of original diagnosis and date of first event (recurrence or
death). Patients still alive at the end of the study were censored at
the date of last follow-up.
RNA extraction. A small piece of tissue was prepared on a glass
slide as a diagnostic smear with subsequent H&E staining. Slides
were reviewed by a pathologist to determine if tumour cells were
present.
Total RNA was extracted from 12 CNS PNET and 1 pine-
oblastoma frozen tumour samples. In all, 40–50mg of tissue was used
for extraction using the mirVana miRNA Isolation kit (Invitrogen,
Carlsbad, CA, USA). For cell culture experiments, RNA was extracted
from harvested cells using RNA STAT60 (Amsbio, Abingdon, UK)
following the manufacturer’s instructions. After extraction, RNA was
treated with DNAse (Promega, Madison, WI, USA; 12m) at 37 1C for
30min. RNA quantity and quality was measured using a Nanodrop
ND1000 spectrophotometer (Nanodrop, Wilmington, DE, USA) and
an Agilent 2100 Bioanalyser (Agilent Technologies, Santa Clara, CA,
USA).
Gene expression microarray analysis. RNA from 10 CNS PNETs
and 1 pineoblastoma were run on Affymetrix U133 plus 2.0 arrays.
Three CNS PNETs were recurrences, 1 paired, plus 1 second
surgery sample. Arrays were run by the NASC Affymetrix service
(National Arabidopsis Stock Centre, University of Nottingham,
Nottingham, UK) according to the manufacturer’s recommenda-
tions (Affymetrix).
Raw data were processed using the robust multiarray average
algorithm using Expression Console software (Affymetrix). Hier-
archical clustering was performed in Spotfire DecisionSite for
Functional Genomics (TIBCO Software Inc, Palo Alto, CA, USA).
Euclidean distance measure and weighted pair-group average
clustering method were used. Principal component analysis (PCA)
and class comparisons were performed in GeneSpringGX 11.2
(Agilent Technologies). Genes differentially expressed between
subgroups were identified using a t-test with a Benjamini and
Hochberg multiple test correction (Benjamini and Hochberg,
1995). Genes with a P-value o0.05 were considered significant.
Microarray data from this study are available at NCBI Gene
Expression Omnibus (http:/www.ncbi.nlm.nih.gov/geo/) under the
accession number GSE19404.
Quantitative PCR. cDNA synthesis was carried out using the
Revertaid cDNA synthesis kit (Fermentas, St Leon-Rot, Germany)
using 500 ng RNA. A control was included for each sample where
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reverse transcriptase was excluded from the reaction mix to test for
genomic DNA contamination in subsequent PCR reactions.
PCR reactions were carried as previously described (Rogers et al,
2012a). Primer sequences and annealing temperatures are dis-
played in Table 1. Data were normalised using GAPDH. Each
cDNA sample was analysed in triplicate. Primer efficiency and
precision were calculated using a standard curve. Relative expres-
sion to a calibrator sample was calculated using the Pfaffl
equation (Pfaffl, 2001). For tumour samples, temporal lobe RNA
(BioChain, Newark, CA, USA) was used as a calibrator.
Cell culture. PFSK1 cells were obtained from the American Type
Culture Collection (ATCC, Teddington, UK). Cells were cultured
in standard humidified incubators at 5% CO2 in RPMI-1640
medium (Invitrogen) supplemented with 15% fetal bovine serum
(PAA Laboratories, Pasching, Austria) and antibiotics. For
experiments, cells were seeded in 24-well plates and incubated
overnight. The following day cells were treated with recombinant
wnt3a protein at 100 ngml–1 (R&D Systems, Abingdon, UK) or
vehicle (PBS, 0.1% BSA). At specified time points, cells were
harvested for RNA extraction.
Immunofluorescence. Cells were seeded in chamber slides. The
following day cells were treated with recombinant wnt3a protein at
100 ngml–1 (R&D Systems) or vehicle (PBS, 0.1% BSA). After 24 h,
cells were fixed by incubating with 4% PFA for 20min. Immuno-
Table 1. Primer sequences
Gene name Forward primer sequence (50–30) Reverse primer sequence (50–30) Annealing temperature
LEF1 AAGCCCAGCACTTGAATTGT ATGACAGTTTTGGGCAAAGG 62 1C
ZIC2 CTAATCTCCATGCCCACGTT GAACGCAATCCGGAGTTTTA 59 1C
MSX1 GAACGCAATCCGGAGTTTTA CAGGAGACATGGCCTCTAGC 63 1C
PLXNB2 TACGATGCCTTCCTGACCTC TCTTGGAACTGCTCCCAGTC 61 1C
AXIN2 TGCTTTCGTGGAAATGACAG AGGTGTGTGGAGGAAAGGTG 61 1C
GAPDH ATGTTCGTCATGGGTGTGAA GTCTTCTGGGTGGCAGTGAT 59–63 1C
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Figure 1. b-Catenin immunohistochemistry displayed different patterns of staining in different tumours; cytoplasmic (A), low nuclear (o10%
nuclei) (B) or high nuclear (410% nuclei) (C). A significant association was seen between WNT/b-catenin pathway activation and a better OS for
CNS PNETs (D—OS P¼ 0.030). An association just below significance was seen for PFS (E—PFS P¼ 0.063). Pathway activation was predicted by
b-catenin nuclear staining (N) compared with cytoplasmic or negative staining (C/O). A significant association was also found with OS and PFS
when the CNS PNETs displaying high nuclear staining (N high) were compared with the rest of the CNS PNET cohort (Rest) (F—OS P¼ 0.025,
G—PFS P¼0.036).
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fluorescence was carried out as previously described (Rogers et al,
2012b). Briefly, after blocking in 5% normal goat serum (Invitrogen)
and 0.25% Triton X-100 (Sigma-Aldrich, Poole, UK) for 1 h at room
temperature, cells were incubated with mouse anti-b-catenin
primary antibody at 4 1C overnight (1 in 200, 2677 Cell Signaling
Technology). For signal detection, cells were incubated with Alexa
Fluor 555 goat anti-mouse secondary antibody (1 in 500, Invitrogen)
at room temperature for 1 h, then mounted using Vectashield
containing 40, 6-diamidinophenylindole (Vector Laboratories,
Peterborough, UK). Images were obtained using a Leica DMRM
fluorescent microscope (Nikon, Digital sight-USB (H), Kingston-
upon-Thames, UK) equipped with a Nikon digital camera. NIS
elements software was used to capture images (Nikon).
Copy number analysis. Previously published 100K SNP array
data were used to analyse DNA copy number changes (GEO
accession number GSE12370; Miller et al, 2011). Affymetrix CEL
files were imported into Genespring GX11.2 (Agilent Technologies).
Tumour data were either normalised using matched constitutional
DNA (available for 7 samples) or the 270 HAPMAP samples (The
International HapMap Consortium, 2003). GISTIC analysis was
performed using Genespring GX11.2. Regions with a q-valueo0.25
were deemed significant.
RESULTS
We have analysed WNT/b-catenin pathway status using b-catenin
IHC for additional CNS PNETs to add to our previously published
cohort (Rogers et al, 2009). Our original study contained 23
primary CNS PNETs plus 5 pineoblastomas. We have almost
doubled the size of our cohort, adding 19 primary CNS PNETs and
4 pineoblastomas. We used nuclear localisation of b-catenin to
define WNT/b-catenin pathway activation. Nuclear localisation
was seen in 11 of the 42 primary CNS PNETs (26%), 8 displaying
high staining and 3 low (Figures 1A–C). Eight CNS PNET
recurrences were analysed in total (two new samples). Four
displayed high and two low nuclear staining. Two pineoblastomas
(22%) displayed low nuclear staining.
Clinical information was available for 33 CNS PNET samples
for OS analysis and 30 samples for PFS. A significant association
between b-catenin nuclear staining and a better OS was identified
in the CNS PNET cohort (P¼ 0.03). An association just below
significance was found with PFS (P¼ 0.063). A slightly higher
significance was obtained for the CNS PNET cohort if the high
nuclear group was analysed against the rest of the cohort (OS
P¼ 0.025, PFS P¼ 0.036; Figures 1D–G). The median survival for
the CNS PNETs with b-catenin nuclear staining was 252 months
with a 5-year survival rate of 52% compared with a median survival
of 24 months and a 5-year survival rate of 13% in the rest of the
CNS PNETs.
The number of pineoblastomas was too low to carry out a
statistical analysis of survival data. However, of the two tumours
displaying low nuclear positivity for b-catenin, one died after 15
months but the other is alive, progression free, after 169 months.
The median survival for the six pineoblastomas showing either
cytoplasmic or negative b-catenin staining was 36 months with a
5-year survival rate of 17%, which is similar to the CNS PNETs
displaying this b-catenin staining pattern.
To understand the biological effects of WNT/b-catenin pathway
activation, we analysed mRNA expression array data. We initially
analysed a published cohort of 33 primary CNS PNETs (GEO
accession number GSE14295; Li et al, 2009). As b-catenin staining
had not been carried out on this cohort we used AXIN2 expression
to define pathway activation. AXIN2 has previously been shown to
be induced by the WNT/b-catenin pathway (Jho et al, 2002).
Increased AXIN2 gene expression has also been seen in WNT
subgroup medulloblastomas (Kool et al, 2008; Northcott et al,
2010). We validated our findings from this cohort using array data
generated from a subset of our IHC cohort, for which we could
define pathway status using b-catenin IHC.
Initial analysis of the published cohort of 33 primary CNS
PNETs identified seven tumours with high AXIN2 expression
(signal value above 3500, Supplementary Figure 1) and therefore
with predicted pathway activation. Only three of the tumours with
high AXIN2 expression had available survival data. The median
survival for these tumours was 72 months with a 5-year survival
rate of 60%, compared with a median survival of 13.2 months and
5-year survival rate of 9% in the rest of the cohort (n¼ 19). This
suggested the tumours with WNT/b-catenin pathway activation
had a better prognosis, in agreement with our IHC analysis.
Statistical comparison of the tumours with and without pathway
activation identified 86 probes with significantly different expres-
sion (Supplementary Table 1). A number of WNT/b-catenin
pathway genes were identified including AXIN2, WNT3A and
LEF1. Analysis of the gene list using ingenuity pathway analysis
Table 2. Summary of the top biological functions identified from IPA for
the genes displaying a significant difference in expression between CNS
PNETs predicted to have WNT/b-catenin pathway activation and the rest
of the cohort
Name P-value Number of
molecules
Diseases and disorders
Dental disease 1.10E-03-
1.65E-02
2
Antimicrobial disease 3.32E-03-
3.32E-03
1
Cancer 3.32E-03-
4.67E-02
20
Cardiovascular disease 3.32E-03-
9.92E-03
2
Developmental disorder 3.32E-03-
4.55E-02
6
Molecular and cellular functions
Cell cycle 1.08E-05-
2.95E-02
5
Cellular compromise 2.99E-04-
3.59E-02
5
Cellular development 4.78E-04-
4.75E-02
18
Cellular growth and proliferation 9.59E-04-
4.87E-02
17
Cell morphology 1.98E-03-
4.23E-02
4
Physiological system development and function
Digestive system development and
function
1.22E-06-
2.62E-02
6
Organ development 1.22E-06-
3.27E-02
8
Haematological system development
and function
1.08E-05-
4.23E-02
5
Humoral immune response 1.08E-05-
9.59E-04
2
Tissue development 8.83E-05-
4.59E-02
11
Abbreviations: CNS PNET¼ central nervous system primitive neuroectodermal tumour;
IPA¼ ingenuity pathway analysis.
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revealed significant enrichment for genes involved in cellular
proliferation and tissue development. Many of the genes have also
been linked to cancer (Table 2).
The enrichment for genes involved in tissue development
suggested this process might be affected in the tumour cells. We
looked at the expression of neuronal markers using the array data.
Although none were identified in the statistical comparisons, a
trend for lower expression of markers of neuronal differentiation
was seen in the tumours with WNT/b-catenin pathway activation
(Figures 2A–C).
We analysed the protein expression of the neuronal markers map2
and synaptophysin by IHC. High positive staining for map2 was seen
in 16 out of 33 primary CNS PNETs analysed. Low or negative
staining was seen in the remaining tumours (Figure 2D, E). None of
the CNS PNETs displaying high map2 staining displayed high b-
catenin nuclear staining. Four recurrences were analysed; two
displaying high and two low or negative map2 expression. The
two tumours displaying high map2 expression displayed cyto-
plasmic b-catenin only. Five pineoblastomas were analysed; two
displaying high and three low map2 expression. One pine-
oblastoma, with low map2 staining, displayed low b-catenin
nuclear staining (Table 3).
Positive staining for synaptophysin was seen in 19 out of 39
primary CNS PNETs analysed (Figure 2F). The majority of CNS
PNETs with nuclear b-catenin staining were negative for
synaptophysin (60%). Only 4 out of 19 CNS PNETs that were
positive for synaptophysin displayed nuclear staining for b-catenin
(two high and two low nuclear staining). Three out of five
recurrences displayed high synaptophysin expression, one of which
also displayed high and one low b-catenin nuclear staining. Only
one out of eight pineoblastomas was negative for synaptophysin,
which was one of two tumours displaying nuclear positivity for
b-catenin (Table 3).
To confirm the gene list identified from the expression data
published by Li et al (2009) was associated with WNT/b-catenin
pathway status, we looked at the expression of these genes using
mRNA expression array data, we generated from 11 tumours and
we analysed it in our IHC cohort for which RNA was available. All
tumours had predicted WNT/b-catenin pathway status from b-
catenin IHC analysis, three with nuclear staining (active) and eight
without nuclear staining (inactive). We grouped the tumours using
the gene list identified from Li et al’s data, using hierarchical
clustering and PCA. The tumours segregated into two groups
according to b-catenin status, confirming the gene list was
associated with WNT/b-catenin pathway activation (Figure 3).
Interestingly, one primary and recurrent pair were analysed
(CNS PNET 07 and 07R), which did not cluster together. Central
nervous system PNET 07 was found in the WNT group and CNS
PNET 07R in the non-WNT group. This agrees with the pathway
status for the two tumours, defined by b-catenin IHC, with CNS
PNET 07 showing nuclear staining and CNS PNET 07R only
cytoplasmic. In addition, in our previous study a mutation in the
b-catenin gene was found in CNS PNET 07 but not CNS PNET
07R (Rogers et al, 2009). These results suggest the primary and
recurrent tumours were biologically different.
Four genes from the identified gene list, LEF1, ZIC2, MSX1 and
PLXNB2, were validated using qPCR. These genes were linked to
the WNT/b-catenin pathway and/or CNS development. Each gene
displayed a significant correlation between qPCR and array data.
High expression was seen in the tumours with WNT/b-catenin
pathway activation, in agreement with the array data (Figure 4).
To further confirm the association between the identified gene
list and WNT/b-catenin pathway activation, the CNS PNET cell
line PFSK1 was treated with recombinant wnt3a protein to activate
the pathway. Without wnt3a treatment, the WNT/b-catenin
pathway was not active in PFSK1 wells, demonstrated by
cytoplasmic localisation of b-catenin. Nuclear localisation of
b-catenin was only seen after treatment with wnt3a protein
(Figure 5A). RT–PCR demonstrated that AXIN2 expression was
induced in wnt3a-treated cells but was not expressed in vehicle-
treated cells (Figure 5B). A significant increase in expression of
three genes; MSX1, ZIC2 and PLXNB2, selected from the list
associated with WNT/b-catenin pathway activation, was seen
following wnt3a treatment. This suggests the upregulation of these
genes found in CNS PNETs with WNT/b-catenin pathway
activation was directly induced by the pathway (Figure 5C).
We compared the gene list we identified associated with
WNT/b-catenin pathway activation in CNS PNET with previously
published gene lists associated with WNT/b-catenin pathway sub-
group medulloblastomas (Kool et al, 2008; Northcott et al, 2010). In
all, 19 out of the 86 genes on our gene list were also linked to WNT
subgroup medulloblastomas (Supplementary Table 2). These included
genes in the WNT pathway (AXIN2 and LEF1) and genes linked to
brain development (JAG2, LAMA5, EFHD1 and ZIC2).
We additionally analysed CNS PNET genomic copy number
data, which we have previously published (Miller et al, 2011), to see
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Figure 2. Tumours predicted to have WNT/b-catenin pathway activation displayed a lower gene expression level of the neuronal markers
synaptophysin (A), MAP2 (B) and b-tubullin III (C). Expression data were taken from the array data published by Li et al. (2009) (GEO accession
number GSE14295). 16 out of 33 CNS PNETs displayed high map2 protein expression (D). The remaining tumours displayed low or negative
staining (E). 19 out of 39 CNS PNETs also displayed positive protein staining for synaptophysin (F).
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if specific changes were associated with WNT/b-catenin pathway
activation. A subset of the tumour samples from Miller et al’s study
were included in the IHC cohort analysed for b-catenin. Figure 6
displays an overview of the copy number changes across the
genome. Regions of significant gain or loss were identified using
GISTIC analysis. An independent analysis was carried out for CNS
PNETs with and without WNT/b-catenin pathway activation.
Only four CNS PNETs with WNT/b-catenin pathway activation
had available copy number data limiting the power of analysis.
Copy number data were available for eight CNS PNETs without
pathway activation. Very few overlapping regions of gain or loss
were identified in tumours with and without pathway activation.
The only overlapping regions of significant copy number change
were gain of two loci on 2p and loss of one locus on 11p.
Significant regions of copy number gain seen in tumours with
WNT/b-catenin pathway activation included chromosome 2 and
Table 3. Immunohistochemistry results for b-catenin, map2 and
synaptophysin analysed on CNS PNET and pineoblastoma cohorts
Tumour
type
Primary/
recurrence
b-Catenin MAP2 Synaptophysin
CNS PNET Primary Negative Negative Negative
CNS PNET Primary Negative High
positive
Positive
CNS PNET Primary Negative High
positive
Negative
CNS PNET Primary Negative Positive
CNS PNET Primary Negative Positive
CNS PNET Primary Cytoplasmic High
positive
Negative
CNS PNET Primary Cytoplasmic Negative Negative
CNS PNET Primary Cytoplasmic Low
positive
Positive
CNS PNET Primary Cytoplasmic Low
positive
Positive
CNS PNET Primary Cytoplasmic High
positive
Positive
CNS PNET Primary Cytoplasmic Low
positive
Negative
CNS PNET Primary Cytoplasmic High
positive
Negative
CNS PNET Primary Cytoplasmic Low
positive
Negative
CNS PNET Primary Cytoplasmic High
positive
Negative
CNS PNET Primary Cytoplasmic Negative Positive
CNS PNET Primary Cytoplasmic High
positive
Positive
CNS PNET Primary Cytoplasmic High
positive
Positive
CNS PNET Primary Cytoplasmic High
positive
Negative
CNS PNET Primary Cytoplasmic High
positive
Positive
CNS PNET Primary Cytoplasmic High
positive
Positive
CNS PNET Primary Cytoplasmic High
positive
Positive
CNS PNET Primary Cytoplasmic Negative Negative
CNS PNET Primary Cytoplasmic Negative Positive
CNS PNET Primary Cytoplasmic High
positive
Negative
CNS PNET Primary Cytoplasmic Low
positive
CNS PNET Primary Cytoplasmic Positive
CNS PNET Primary Cytoplasmic Positive
CNS PNET Primary Cytoplasmic Negative
CNS PNET Primary Cytoplasmic Negative
CNS PNET Primary Cytoplasmic Negative
CNS PNET Primary Low nuclear Negative Positive
CNS PNET Primary Low nuclear High
positive
Negative
CNS PNET Primary Low nuclear High
positive
Positive
Table 3. ( Continued )
Tumour
type
Primary/
recurrence
b-Catenin MAP2 Synaptophysin
CNS PNET Primary High
nuclear
Negative Negative
CNS PNET Primary High
nuclear
Negative Negative
CNS PNET Primary High
nuclear
Negative Negative
CNS PNET Primary High
nuclear
Low
positive
Negative
CNS PNET Primary High
nuclear
Low
positive
Positive
CNS PNET Primary High
nuclear
Low
positive
Negative
CNS PNET Primary High
nuclear
Positive
CNS PNET Recurrence Cytoplasmic High
positive
Negative
CNS PNET Recurrence Cytoplasmic High
positive
Positive
CNS PNET Recurrence Low nuclear Positive
CNS PNET Recurrence High
nuclear
Low
positive
Negative
CNS PNET Recurrence High
nuclear
Negative Negative
CNS PNET Recurrence High
nuclear
Positive
Pineoblastoma Primary Negative Low
positive
Positive
Pineoblastoma Primary Negative High
positive
Positive
Pineoblastoma Primary Cytoplasmic Low
positive
Positive
Pineoblastoma Primary Cytoplasmic High
positive
Positive
Pineoblastoma Primary Cytoplasmic Positive
Pineoblastoma Primary Cytoplasmic Positive
Pineoblastoma Primary Low nuclear Low
positive
Negative
Pineoblastoma Primary Low nuclear Positive
Abbreviation: CNS PNET¼ central nervous system primitive neuroectodermal tumour.
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12q (Supplementary Table 3). Only one small region of loss on
11p was significant (Supplementary Table 4). Significant gain was
seen on most chromosomes in CNS PNETs without pathway
activation. This included gains along chromosomes 5, 7, 9q, 14 and
17 (Supplementary Table 5). Copy number loss was seen on
chromosomes 3p, 6p, 9p, 11p, 12q and 16q (Supplementary Table 6).
DISCUSSION
We have previously published data demonstrating a potential
association between WNT/b-catenin pathway activation and a
better prognosis in CNS PNET. However, the data did not reach
significance (Rogers et al, 2009). In this study, we have almost
doubled the size of our cohort, which enabled us to identify
a significant link to a better prognosis. We additionally identified a
gene expression signature linked to pathway activation. This
included a number of genes involved in the development of the
CNS suggesting pathway activation in the tumours may be
disrupting this process.
Our data suggest WNT/b-catenin pathway status, measured by
b-catenin IHC, could be used as a prognostic marker for CNS
PNETs. The link between pathway activation and a better
prognosis has also been identified in medulloblastoma (Ellison
et al, 2005; Gajjar et al, 2006; Ellison et al, 2010), where pathway
status is now being planned to be used for disease risk stratification
in forthcoming medulloblastoma clinical trials (Pizer and Clifford,
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Figure 3. Heat map of hierarchical clustering of an independent cohort of tumours confirmed the identified gene list was associated with WNT/
b-catenin pathway status (A). The gene list identified from the statistical analysis of the expression data published by Li et al (2009) (defined by
AXIN2 expression) was used to cluster mRNA expression array data generated from an independent cohort of 11 tumours. The WNT/b-catenin
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WNT/b-catenin pathway activation are highlighted in red and those without in blue. The red and blue circles highlight the two groups found in the
hierarchical clustering, which also segregated together in the PCA analysis, particularly along x axis, representing principal component 1, which
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Figure 4. qPCR validation of selected genes; LEF1 (A), ZIC2 (B), MSX1
(C) and PLXNB2 (D). All displayed a significant correlation with mRNA
expression array data (LEF1 r¼0.701, P¼0.05; ZIC2 r¼0.775,
P¼0.02; MSX1 r¼ 0.822, P¼0.01; PLXNB2 r¼0.714, P¼ 0.05).
A difference between tumours with and without WNT/b-catenin pathway
activation (defined using b-catenin IHC) was seen for each gene.
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2009; Ellison et al, 2011). If the association with survival can be
confirmed in independent cohorts, pathway status may be able to
be used for stratification of CNS PNETs as well. However, the
prognosis for medulloblastomas with WNT/b-catenin pathway
activation is much better than CNS PNET. The 5-year OS rate for
CNS PNETs with pathway activation was 52% compared with
medulloblastomas where the WNT subgroup had a 5-year OS rate
of 92–95% (Ellison et al, 2005; Kool et al, 2012). In fact, even
medulloblastomas without WNT/b-catenin pathway activation had
a better 5-year OS rate (65%) than WNT CNS PNETs (Ellison et al,
2005).
The association of WNT/b-catenin pathway activation with a
better prognosis in both CNS PNET and medulloblastoma differs
to what has been found in other types of cancer including colon,
hepatocellular and breast cancer (Lin et al, 2000; Inagawa et al,
2002; Bondi et al, 2004). This might suggest pathway activation is
detrimental to CNS PNET or medulloblastoma survival. However
in medulloblastoma, a mouse model of WNT/b-catenin pathway
activated tumours demonstrated that aberrant pathway activation
induced tumour formation suggesting it does have a role in tumour
development (Gibson et al, 2010). This may also be the case in
CNS PNET. If a pathogenic role can be proven, the WNT/b-
catenin pathway provides a potential target for future therapies
that would be applicable in a quarter of CNS PNET patients.
By utilising gene expression array data published by Li et al
(2009), we identified an expression signature linked to WNT/b-
catenin pathway activation. Analysing the identified gene list in our
independent expression array data enabled us to confirm the gene
expression signature was linked to pathway activation. A number
of genes on the list are involved in CNS development suggesting
pathway activation may be affecting this process in the tumours. If
the normal developmental process was disrupted, preventing cells
from terminally differentiating, cells would remain in a more
proliferative state that could lead to tumour development.
The WNT/b-catenin pathway has a complex role during
development of the CNS. Developmental timing alters the
functional impact of pathway activation on cortical neuronal
precursor cells (Hirabayashi and Gotoh, 2005). At earlier time
points in development, stabilisation of b-catenin results in
expansion of the precursor cell population and enlargement of
the cerebral cortex surface area (Chenn and Walsh, 2002; Zechner
et al, 2003). However, at later time points pathway activation
results in a decreased size of cerebral cortex because of a reduced
proliferative progenitor cell pool and increased apoptosis
(Ivaniutsin et al, 2009). Neural precursor cells cultured in vitro
respond differently to WNT/b-catenin signals depending on when,
in development, the cells were isolated. Cells isolated earlier in
embryonic development show an increase in proliferation in
response to WNT signals (Viti et al, 2003; Israsena et al, 2004).
Whereas, in those isolated later in development, neuronal
differentiation is induced (Hirabayashi et al, 2004; Muroyama
et al, 2004).
If the WNT/b-catenin pathway was aberrantly activated in
neural precursor cells during the earlier phase of embryonic
development, neuronal differentiation would be inhibited and the
cells would remain in a proliferative state creating more favourable
conditions for tumour development. The lower level of gene
and protein expression of neuronal markers we demonstrated in
CNS PNETs with WNT/b-catenin pathway activation compared
with those without suggested these tumours show little neuronal
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differentiation supporting this hypothesis. A similar phenotype has
been seen in a mouse model of CNS PNET (Momota et al, 2008).
Tumours developed following WNT/b-catenin pathway activation
in conjunction with Myc expression and p53 knockout. Regions of
differentiation were seen in the resulting tumours, but not in cells
displaying nuclear b-catenin. In addition, in a model of WNT
subgroup medulloblastoma, WNT/b-catenin pathway activation
inhibited neuronal differentiation of cells in vitro (Rogers et al,
2012b).
Many of the genes that displayed significantly higher expression
in the WNT/b-catenin pathway activated tumours encode for
proteins with a function in CNS development. MSX1 is a
homeobox gene, which is expressed in many different tissues
during development including the CNS, where it has a role in
neural tube development and inhibition of neuronal differentiation
(Liu et al, 2004; Ramos and Robert, 2005). Upregulated expression
has been demonstrated after WNT/b-catenin pathway activation,
including in development and cancer (Willert et al, 2002; Ramos
and Robert, 2005; Miller et al, 2007; Revet et al, 2010). ZIC2 is a
member of a family of zinc-finger transcription factors, which are
involved in early neuronal development and may be involved in
maintaining cell pluripotency (Warr et al, 2008; Brown and Brown,
2009; McMahon and Merzdorf, 2010). ZIC2 was downregulated in
medulloblastoma compared with normal cerebellum (Pfister et al,
2007b). However, upregulated expression of ZIC2 was found in
meningioma (Aruga et al, 2010). PLXNB2 is a member of the
plexin family of proteins, which have a role in axon guidance
(Perala et al, 2005). It is expressed in the CNS during embryonic
development and has been shown to be expressed by neuroepithe-
lial cells at stages critical in their development (Worzfeld et al,
2004).
A number of the genes that we identified as linked to WNT/b-
catenin pathway activation in CNS PNET have also been identified
in WNT subgroup medulloblastomas (Kool et al, 2008; Northcott
et al, 2010), suggesting these genes maybe important to both
tumour types. Overlapping genes included some which function in
CNS development. JAG2 is a member of the NOTCH pathway,
which is known to have important roles during the development of
the CNS. NOTCH signalling has been shown to maintain cells in a
progenitor state, inhibiting differentiation (de la Pompa et al, 1997;
Yun et al, 2002). LAMA5 encodes for the alpha chain of the
extracellular matrix protein laminin 5. Laminins mediate attach-
ment, migration and organisation of cells into tissue during
development including development of the CNS (Libby et al,
2000). EFHD1 has been shown to display increased expression
during neuronal differentiation (Tominaga and Tomooka, 2002).
Genes involved in embryonic development, many of which have
a neuronal-specific function, were also included in the list that did
not overlap with genes showing upregulation in WNT subgroup
medulloblastoma, including MSX1 and PLXNB2. WNT3A forms
part of the WNT/b-catenin pathway, which is involved in the control
of CNS development. In particular, WNT3A has been shown to be
involved in promotion of the expansion of hippocampus progenitor
cells (Lee et al, 2000). TLX1 is involved in neuronal fate specification
WNT inactive WNT active
Gain
Loss
Ch
ro
m
os
om
e
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
Figure 6. Heatmap visualisation of genome-wide copy number data for 12 primary CNS PNETs with or without WNT/b-catenin pathway
activation. Pathway activation was determined by b-catenin IHC where nuclear localisation represented pathway activation. Copy number data
were generated using Affymetrix 100K SNP arrays. Each column represents a tumour sample.
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(Cheng et al, 2004, 2005; Guillemot et al, 2006), KCTD11 is a marker
and regulator of neuronal differentiation (Gallo et al, 2002) and
PCP4L1 is expressed in the developing brain including the cerebral
cortex (Bulfone et al, 2004).
Through analysis of genomic copy number data from an
overlapping cohort of tumours, we were able to identify specific
changes significantly enriched for in WNT/b-catenin pathway
active or inactive CNS PNETs. The number of tumours analysed
was relatively low limiting the power of the results. However, very
few regions identified overlapped between CNS PNETs with or
without pathway activation. Interestingly, a number of the regions
identified in the WNT inactive group were previously found by
Miller et al (2011). We used a subset of the data from this study in
our analysis. Miller et al (2011). identified significant gain of
5q31.3, which we found to be associated with non-WNT tumours.
This region contains genes from the protocadherin gamma family,
which have a role in neuronal development (Akins and Biederer,
2006). Miller et al (2011) also identified loss at 9p21.3 and 3p14.2,
which we found to be associated with non-WNT tumours in our
analysis. The locus lost on 9p21.3 contains the tumour suppressors
CDKN2A and B. In medulloblastoma, WNT active tumours have
been associated with chromosome 6 monosomy (Ellison et al,
2011). We did not find this association in CNS PNET.
A recent array-based study of CNS PNETs identified three
molecular subgroups (Picard et al, 2012). A proportion of the
tumours from Li et al’s study, which we analysed, were included in
the study by Picard et al. Three out of four tumours that we
defined as having WNT/b-catenin pathway activation were found
in group 3. Only 3 out of 17 tumours we defined as having no
pathway activation were found in group 3. This suggests CNS
PNETs with WNT/b-catenin pathway activation have a biological
profile similar to group 3 tumours. The gene expression and
clinical profile of group 3 tumours supports this conclusion. MSX1
and ZIC2 both displayed significantly higher gene expression in
group 3 tumours. They also displayed downregulation of neural
differentiation genes. Genes from the WNT pathway were signi-
ficantly enriched in group 3 tumours. Group 2 tumours displayed
downregulation of the WNT/b-catenin pathway and group 1
tumours displayed upregulation of the non-canonical WNT path-
way. In addition, group 3 tumours had a better prognosis than
other CNS PNETs.
Picard et al also linked genomic copy number changes to the
CNS PNET subgroups they identified. 9p21.3 loss, which we saw in
non-WNT tumours, was seen in groups 2 and 3. 8p gain, which we
saw in non-WNT tumours, was seen by Picard et al in group 2
tumours. Interestingly, Picard et al found chromosome 2 gain to be
associated with group 1 tumours. We found chromosome 2 gain to
be associated with WNT active tumours, which does not fit with
the expression profile of WNT active tumours, which was closer to
group 3 tumours. However, gain of chromosome 2 was seen by
Picard et al in some group 3 tumours. In addition, we were only
able to analyse a small number of tumours limiting the power of
analysis and the conclusions we could make.
Pineoblastomas were included in our analysis. These tumours
resemble CNS PNETs histologically and are treated on similar
protocols (Pizer et al, 2006; Louis et al, 2007). We found two out of
nine pineoblastomas displayed WNT/b-catenin pathway activa-
tion. Very little is known about the pathogenesis of pine-
oblastomas. Therefore, our results add valuable information and
understanding of their underlying tumour biology.
In conclusion, we have demonstrated a significant link between
WNT/b-catenin pathway activation and a better prognosis in CNS
PNET suggesting it is a potential prognostic marker, which could
be used to stratify patient disease risk. We have identified an
expression signature linked to pathway activation, which contains
genes involved in the control of CNS development suggesting
aberrant pathway activation in the tumours maybe disrupting this
process. If differentiation of progenitor cells is inhibited, cells will
remain in a proliferative state creating more favourable conditions
for tumour development.
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